Clearmicin

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Clearmicin

Property Description
Active ingredient Clarithromycin
Form Tablets, oral suspension, intravenous solution
Pharmacological class Macrolide antibiotic
Common use Systemic treatment of bacterial infections
Origin Semi-synthetic (derived from Erythromycin)

Defining Clearmicin: A Macrolide Antibiotic

Clearmicin is a prescription-only medicinal product whose active ingredient is Clarithromycin, which is precisely classified as a macrolide antibiotic and a systemic antimicrobial agent. Clarithromycin is a semi-synthetic derivative, created from the naturally occurring macrolide, Erythromycin, through a chemical modification at the C-6 position. This structural change is clinically recognized for improving the medicine's acid stability and gastrointestinal tolerability compared to the prototype. This means the medicine is designed to be absorbed more consistently when taken orally. As a single-ingredient product, it is most commonly supplied in oral dosage forms, including film-coated tablets and granules for oral suspension, although preparations for intravenous administration are also utilized. This second-generation macrolide is frequently used as an alternative to penicillin in patients who have known penicillin allergies.

How Clearmicin Acts: General Antimicrobial Purpose

The overarching purpose of Clearmicin is to counteract infections caused by a wide spectrum of susceptible bacteria, demonstrating broad activity against both typical and atypical respiratory pathogens. This confirms the drug is a foundational tool used by doctors to combat widespread bacterial illness, including respiratory tract infections. Its action relies on the mechanism of being a protein synthesis inhibitor: it penetrates the bacterial cell and works by binding to the 50S ribosomal subunit, which is essential for the bacteria to build their necessary structural and functional proteins. By preventing the bacteria from growing and replicating, the compound effectively stops the spread, exerting a primary bacteriostatic agent effect and facilitating the body’s own defenses in overcoming systemic bacterial illnesses.

Regulatory References

  1. Clarithromycin Drug Information (MedlinePlus)

What side effects are possible with Clearmicin?

Possible Side Effects and Safety Information: Clearmicin

Clearmicin (a hypothetical macrolide antibiotic) is generally well-tolerated, but like all medications, it can cause side effects. Most side effects are mild to moderate and resolve upon discontinuation of the drug. Always consult your healthcare provider if you experience persistent or severe reactions.


Common Side Effects (Affecting up to 1 in 10 people)

System Side Effect
Gastrointestinal Nausea, vomiting, diarrhea, abdominal pain
Nervous System Headache
Skin Rash

Serious or Less Common Side Effects (Require immediate medical attention)

Serious Allergic Reaction (Anaphylaxis): Symptoms may include difficulty breathing, severe dizziness, swelling of the face, tongue, or throat, and widespread rash. Seek emergency care immediately if these occur.

Liver Problems: Rare but serious liver toxicity has been reported. Symptoms of liver distress may include unusual fatigue, dark urine, pale stools, and jaundice (yellowing of the skin or eyes).

Cardiac Rhythm Changes: Clearmicin may prolong the QT interval on an electrocardiogram, which can lead to a serious, irregular heart rhythm (Torsades de Pointes). This risk is increased in patients with pre-existing heart conditions or those taking other QT-prolonging drugs.

Safety Precautions

Drug Interactions: Clearmicin can interact with numerous medications, including blood thinners (like warfarin), statins, and certain heart medications, potentially increasing their concentration and risk of toxicity. Always inform your doctor of all current medications, supplements, and herbal products.

Special Populations: Use with caution in patients with significant liver impairment. Clearmicin's safety during pregnancy and breastfeeding has not been established and should be discussed with a doctor.

Overdose and Emergency Response

Overdosage with Clearmicin (Clarithromycin) is primarily characterized in regulatory documents by severe gastrointestinal symptoms, including abdominal pain, nausea, vomiting, and diarrhea. Postmarketing surveillance also reports CNS effects such as confusional state and hallucination in severe cases.


The most critical regulatory concern is the potential for life-threatening cardiotoxicity. High systemic exposure carries the documented risk of QT interval prolongation, which may lead to severe Ventricular Tachycardia and the potentially fatal arrhythmia known as Torsades de Pointes. Severe organ injury, including hepatic failure and renal failure, is also a documented outcome.


Due to the significant risk of these severe cardiac events and organ damage, immediate medical attention must be sought in all suspected or confirmed cases of overdose.


Management is based on symptomatic and supportive treatment, as official labeling confirms no specific antidote is known. Regulatory guidance states that procedures such as gastric lavage or administration of activated charcoal may be considered to remove unabsorbed medicine from the stomach. Continuous ECG monitoring is required for observation due to the risk of cardiotoxicity. The elderly and patients with pre-existing hepatic or renal impairment are noted to be at an increased risk of severe toxicity.

Therapeutic Uses of Clearmicin

What Clearmicin treats: main uses and benefits

Clearmicin is a macrolide antibiotic used to treat a wide range of bacterial infections caused by susceptible organisms. Its therapeutic use focuses on infection control, particularly in clinical settings involving acute or unstable symptom patterns. Main applications include conditions characterized by periods of heightened symptoms, such as lower and upper respiratory tract infections, skin and soft tissue infections, and the management of peptic ulcer disease associated with H. pylori.

These applications help address symptom clusters that may become intense or disruptive, offering supportive relief when symptoms interfere with routine activities. The medication is commonly used to help manage conditions presenting with systemic or localized discomfort. It supports the patient during difficult episodes by easing distress. Clearmicin is considered relevant in contexts involving a heightened systemic burden. It may assist with maintaining functional stability and contributing to improved comfort during symptomatic periods, which supports general well-being during symptomatic phases.

Quick Fact: May assist with symptoms related to physical discomfort.

Eligibility and Restrictions for Use

Who can and cannot use Clearmicin?

This medicine is subject to strict eligibility rules based on regulatory labeling concerning underlying health conditions and concurrent medications.

Contraindicated Populations

Clearmicin is strictly contraindicated for use in patients with:

  • Known hypersensitivity to clarithromycin, erythromycin, or any macrolide antibiotic.
  • A history of QT prolongation or ventricular cardiac arrhythmia.
  • Uncorrected electrolyte disturbances (low potassium or magnesium).
  • Severe hepatic failure in combination with renal impairment.
  • Concomitant use of several drugs, including lovastatin, simvastatin, pimozide, cisapride, and ergot alkaloids.

Age and Condition Restrictions

  • Age-Related Eligibility: Safety and efficacy are not established for infants younger than six months. Clearmicin tablets are not recommended for children under 12 years, who must use the oral suspension formulation.
  • Organ Function: Use is restricted and requires careful consideration in patients with severe renal impairment or impaired hepatic function.
  • Pregnancy/Lactation: Use during pregnancy is not recommended, especially during the first trimester, unless no alternative therapy is available. Caution is advised during lactation.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Clearmicin (Clarithromycin) is classified as a potent inhibitor of the CYP3A4 metabolic enzyme and the P-glycoprotein (P-gp) transporter. This dual inhibition alters the body's processing of many co-administered medicines, significantly increasing their systemic exposure and potential for adverse effects, as documented in regulatory sources.


Formal Regulatory Contraindications

Co-administration with the following substances is strictly prohibited due to the high and documented risk of serious toxicity:

  • Ergot Alkaloids (e.g., Ergotamine, Dihydroergotamine): Risk of acute ergot toxicity and severe vasospasm.
  • Selected CNS/Anti-arrhythmic Agents (e.g., Pimozide, Cisapride, Astemizole, Terfenadine): Risk of QT prolongation and life-threatening ventricular arrhythmias.
  • HMG-CoA Reductase Inhibitors (Statins: Lovastatin, Simvastatin): Risk of markedly increased plasma concentration, leading to myopathy and rhabdomyolysis.
  • Lurasidone and Oral Midazolam: Contraindicated due to documented increases in drug exposure.

Other Documented Interactions

Co-administration with Oral Anticoagulants (e.g., Warfarin) may potentiate anticoagulant effects, requiring frequent monitoring of the International Normalized Ratio (INR). Clearmicin is documented to increase the exposure of Digoxin via P-gp inhibition. Furthermore, the combination with Colchicine is contraindicated specifically in patients who have renal or hepatic impairment. The herbal product St. John’s Wort may reduce Clearmicin's plasma concentrations.

Mechanism of Action

Direct Microbial Suppression: Ribosomal Blockade

Clearmicin (Clarithromycin) operates via a precise dual mechanism, commencing with its primary action as an inhibitor of bacterial protein synthesis. The molecule binds specifically and reversibly to the 23S Ribosomal RNA component of the bacterial 50S Ribosomal Subunit. This interaction physically occludes the Nascent Peptide Exit Tunnel, thereby arresting the crucial process of peptide elongation and protein synthesis. This immediate cellular consequence results in a bacteriostatic effect, preventing the growth and replication of susceptible bacteria.

️ Modulation of Host Inflammatory Pathways

Independent of its antimicrobial activity, Clearmicin exerts a secondary immunomodulatory effect on host tissues. The compound concentrates within host phagocytic cells, where it modulates intracellular signaling cascades, specifically those involving the NF-κB transcription factor. This action attenuates the excessive signaling associated with inflammation by reducing the production of pro-inflammatory mediators on host tissues.

️ Mechanistic Constraint: Resistance

The drug's mechanism is constrained by bacterial resistance pathways, including Ribosomal Methylation, which prevents macrolide binding, and the expression of active Efflux Pumps, which physically transport the drug out of the cell before it can reach its ribosomal target.

Dosage and Administration Information

How to use Clearmicin

Clearmicin usage is standardized based on established parameters. The medicine is utilized for administration through oral forms, including immediate-release and extended-release tablets, and oral suspension. For initial treatment in certain clinical scenarios, administration via intravenous (IV) infusion is utilized.


The most common dosing pattern involves taking the immediate-release form twice daily, maintaining a 12-hour interval between doses. Conversely, the extended-release tablet is used once daily. The duration of therapy generally spans 7 to 14 days, though treatment for specific bacterial infections, such as those caused by beta-haemolytic streptococcus, requires a minimum course of 10 days.


Specific procedural constraints govern administration. Extended-release tablets must be ingested with food and must be swallowed whole; they are not intended to be crushed or broken. Immediate-release tablets and suspension may be taken independent of mealtimes. For patients with severely reduced kidney function (creatinine clearance less than 30 mL/min), the total daily dose is reduced by one-half. If a dose is forgotten, it is taken as soon as it is remembered, unless it is close to the next scheduled dose, in which case the missed dose is skipped entirely to avoid doubling the amount taken.

Recent Clinical Evidence

Research evidence / Overview of Studies for Clearmicin

Evidence for Acute Bacterial Respiratory Tract Infections

Clearmicin was studied for its application in conditions involving periods of heightened symptoms affecting the respiratory tract. Research has primarily involved numerous short-term Randomized Controlled Trials (RCTs), where the medicine was evaluated in comparison to other antimicrobial agents previously evaluated in research. These studies typically involved adult populations with mild-to-moderate infections and some pediatric groups.

Researchers monitored outcomes related to physical discomfort and systemic or functional imbalance, such as how signs and symptoms evolved during the study period. Findings describe patterns observed in the studies over the defined short-term follow-up periods. Long-term effects are not fully established for these acute infectious events, as follow-up durations were limited. Growing macrolide resistance in certain bacteria may affect the applicability of patterns observed in older trials to current scientific understanding.


Evidence for H. Pylori Eradication Regimens

Research has explored the role of Clearmicin as one agent in multi-drug regimens, most commonly triple therapy, for conditions involving periods of heightened symptoms related to H. pylori infection and peptic ulcer disease. These studies monitored outcomes related to microbiological clearance—specifically, the H. pylori eradication rate confirmed by testing several weeks after the treatment was completed.

The consistency of the findings were mixed across different regions. The documented increase in Clarithromycin resistance among H. pylori strains introduces uncertainty. The evidence quality varies across studies, and findings in areas with high resistance remain uncertain.


Evidence for Specialized and Chronic Infections (MAC Disease)

Clearmicin was studied for chronic and severe infections, specifically Mycobacterium Avium Complex (MAC) disease. The research here involved controlled clinical trials focused on the drug's use as part of long-term combination regimens for both treatment and prevention. The populations was evaluated in were highly specific, including individuals with advanced immunosuppression.

These studies explored outcomes reflecting daily functioning and physiological strain, along with the elimination of the MAC organism from the bloodstream and tracking long-term follow-up. A significant limitation is that the results apply only to the populations studied—primarily those with severe immunosuppression.


Investigational Research and Non-Antimicrobial Properties

A distinct area of research has been studied for the drug's properties outside of its primary antimicrobial action. This includes trials exploring its use as an adjunct therapy in severe conditions, like sepsis, and for conditions characterized by fluctuating or episodic manifestations such as certain chronic airway diseases. In these specific investigational contexts, findings were mixed. The certainty remains low regarding broad clinical application in these areas.

Frequently Asked Questions (FAQ)

Common questions about Clearmicin (FAQ)


Q: Is Clearmicin the same as other similar treatments I've heard of?

Clearmicin's active ingredient is Clarithromycin. Regulatory documents classify it as a macrolide antibiotic, which is a general class of medicines used to treat bacterial infections. It is a semi-synthetic derivative of an older macrolide called Erythromycin, meaning it was chemically modified from the original substance.


Q: Do I need to take Clearmicin forever?

No. Official regulatory documents define the treatment duration for most bacterial infections as typically spanning 7 to 14 days. For specific bacterial infections, the prescribing information specifies a minimum course of 10 days. The medicine is generally prescribed as a short-term treatment.


Q: Can Clearmicin cause long-term side effects?

Most side effects are described in official labeling as mild-to-moderate and often resolve once the medicine is stopped. However, rare but serious effects, such as liver problems, have been reported in post-marketing surveillance. Regulatory warnings indicate that these effects may necessitate ongoing medical evaluation.


Q: Are there any major food or drink restrictions with Clearmicin?

Official labeling specifies that the extended-release form of Clearmicin must be taken with food to ensure proper absorption. Aside from that, regulatory documents do not list common food items (like dairy or specific fruits) that must be strictly avoided. Official labeling does not provide specific warnings about consuming alcohol with this medicine, though general caution is advised when combining alcohol with any prescription drug.


Q: Is Clearmicin appropriate for people with reduced kidney function?

Regulatory documents restrict or caution use in patients with reduced kidney function. For individuals with severely reduced kidney function (creatinine clearance less than 30 mL/min), official prescribing information specifies that the total daily dose should be reduced by one-half.


Q: Does Clearmicin make you tired or affect energy levels?

Fatigue or generalized tiredness is not listed among the most common side effects in the product labeling. However, side effects like headache are reported. Also, certain serious, but rare, adverse effects like liver problems have been documented which can cause unusual fatigue.


Q: Will Clearmicin affect my ability to drive or operate machinery?

Official product information notes that certain side effects, such as dizziness and headache, may occur while using the medicine. Official warnings suggest that the occurrence of these effects may impair the user's ability to drive or operate machinery.

--TUNNEL

Q: What is the experience of people who have been on Clearmicin for a long time?

Research evidence supporting the drug’s use often involves short-term follow-up periods. Long-term studies are limited to highly specific patient populations, such as those with chronic conditions like Mycobacterium Avium Complex (MAC) disease.


Q: Why is Clearmicin only available by prescription?

The drug is classified as a prescription-only medicine because of its potent mechanism of action and the need for medical guidance. This is necessary to manage the risk of serious side effects, to monitor for proper use against susceptible bacteria, and to mitigate the potential for severe drug interactions with other medications.


Q: Can Clearmicin be taken while pregnant or breastfeeding?

Official labeling states that use during pregnancy is not recommended, particularly in the first trimester. This restriction applies unless a healthcare provider determines that no appropriate alternative therapy is available. Regulatory documents also advise using caution when the medicine is used while breastfeeding.


Q: Is Clearmicin a controlled substance?

Clearmicin's active ingredient, Clarithromycin, is regulated as a prescription-only medicine (a macrolide antibiotic). However, according to regulatory systems, it is not classified as a federally controlled substance in the U.S. or U.K.


Q: Does Clearmicin interact with birth control pills?

Regulatory guidance suggests Clearmicin does not stop the effectiveness of hormonal contraceptives, including the combined birth control pill. However, if the medicine causes severe vomiting or diarrhea, the contraceptive's protection may become compromised.


Q: Can Clearmicin affect my mood or cause anxiety?

Official product labeling documents adverse events that affect the nervous system. These include reports of common effects like headache and, less commonly, reports of anxiety and other psychiatric disorders.


Q: Are there different strengths or forms of Clearmicin?

Yes, Clearmicin is supplied in multiple forms according to regulatory labeling. These include immediate-release and extended-release tablets, and granules for oral suspension, as well as a solution for intravenous use. The prescribing information specifies the available strengths for each form.


Q: How long does Clearmicin stay in your system after you stop taking it?

Official pharmacokinetic information indicates how long the drug remains active in the body. The elimination half-life of the active ingredient is generally reported to be approximately 3 to 7 hours, depending on the specific dosage form.


Q: Do children or teenagers use Clearmicin?

The oral suspension formulation is indicated for use in children from 6 months up to 12 years of age. The tablet forms are not recommended for children under 12 years. Adolescents over 12 years are typically prescribed the standard adult dosage.


Q: What is the proper way to dispose of unused Clearmicin?

Official guidance advises that medicine should not be flushed down a toilet or poured down a drain. Unused or expired Clearmicin should be disposed of through a certified drug take-back program or by following official regulatory guidance for disposal in household trash.


Q: Is Clearmicin indicated for all stages of the condition it treats?

Official regulatory indications usually specify the drug's use for the treatment of mild to moderate infections caused by susceptible bacteria. Clinical studies used for approval often focused on these specific severities and patient populations.


Q: Can Clearmicin affect lab test results?

Yes, the medicine is documented to interfere with certain clinical measurements. This includes possible temporary increases in liver enzyme levels and prolongation of the QT interval on an electrocardiogram (ECG) reading.


Q: Are there any reported cases of overdose with Clearmicin?

Regulatory documents contain information on overdose reports. These have included symptoms ranging from gastrointestinal discomfort to changes in mental status. Regulatory documents state that management of overdose has been supportive.

How should Clearmicin be stored and disposed of?

How to Store and Dispose of Clearmicin (Clarithromycin)

Official regulatory labeling dictates specific storage and disposal requirements for Clearmicin to ensure its stability and prevent environmental harm.

Storage Requirements

  • Dry Product (Tablets/Granules): Store at controlled room temperature, specifically between 20 C and 25 C. Keep the medicine in its tightly closed original container in a dry place.
  • Reconstituted Suspension: Store at ambient temperature, between 15 C and 30 C. The suspension must not be refrigerated and must be used within 14 days of mixing.
  • Child Safety: All medicine must be kept out of the sight and reach of children.

Disposal Requirements

Do not flush Clearmicin down a toilet or pour it down a drain. Dispose of unused or expired medicine through a certified drug take-back program or by following the FDA's guidance for disposal in household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Clearmicin found in:

A-Z Index: